MICROBA LIFE SCIENCES LIMITED (MAP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MAP - MICROBA LIFE SCIENCES LIMITED

Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.06
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.215

27 Mar
2024

0.000

OPEN

$0.21

0.000

HIGH

$0.22

311,985

LOW

$0.21

TARGET
$0.35 62.8% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MAP: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A - 3.9 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 24/06 - (franking Ex-Di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 2020202120222023
EPS Basic xxxxxxxxx-3.8
DPS All xxxxxxxxx0.0
Sales/Revenue xxxxxxxxx5.4 M
Book Value Per Share xxxxxxxxx10.6
Net Operating Cash Flow xxxxxxxxx-12.4 M
Net Profit Margin xxxxxxxxx-233.95 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2020202120222023
Return on Capital Employed xxxxxxxxx-35.17 %
Return on Invested Capital xxxxxxxxx-34.82 %
Return on Assets xxxxxxxxx-29.34 %
Return on Equity xxxxxxxxx-35.17 %
Return on Total Capital xxxxxxxxx-54.25 %
Free Cash Flow ex dividends xxxxxxxxx-12.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 2020202120222023
Short-Term Debt xxxxxxxxx1 M
Long Term Debt xxxxxxxxx0 M
Total Debt xxxxxxxxx1 M
Goodwill - Gross xxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxx32 M
Price To Book Value xxxxxxxxx2.68

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 2020202120222023
Capex xxxxxxxxx3.0 M
Capex % of Sales xxxxxxxxx56.03 %
Cost of Goods Sold xxxxxxxxx12 M
Selling, General & Admin. Exp & Other xxxxxxxxx13 M
Research & Development xxxxxxxxx9 M
Investments - Total xxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

29/02/2024

1

Speculative Buy

$0.35

62.79%

There were no surprises for Morgans within 1H results for Microba Life Sciences given quarterly reporting.

Losses increased to -$11.5m from -$5.7m due to R&D activity ramping-up, acquisition costs and expenses incurred prior to new product launches, explain the analysts.

While no guidance was provided, management expects 2024 will be a breakthrough year, a sentiment the broker goes along with due to the imminent launch of MetaPanel, and the opening of international sales channels.

The Speculative Buy rating and 35c target are maintained.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -3.50 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -2.70 cents.

MAP STOCK CHART